Charles W Francis

Summary

Publications

  1. ncbi request reprint Plasminogen activator inhibitor-1 levels and polymorphisms
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Arch Pathol Lab Med 126:1401-4. 2002
  2. doi request reprint Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
  3. pmc Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, The James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Transfusion 53:382-93. 2013
  4. ncbi request reprint A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications
    Nicole M Kuderer
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Cancer 110:1149-61. 2007
  5. ncbi request reprint Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 110:2339-46. 2007
  6. pmc The platelet as an immune cell-CD40 ligand and transfusion immunomodulation
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:251-60. 2009
  7. pmc Foxp3 regulates megakaryopoiesis and platelet function
    Jamie J Bernard
    Department of Environmental Medicine, University of Rochester, Rochester, NY 14642, USA
    Arterioscler Thromb Vasc Biol 29:1874-82. 2009
  8. pmc Prevention of venous thromboembolism in hospitalized patients with cancer
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4874-80. 2009
  9. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
  10. pmc Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 126:113-8. 2010

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Plasminogen activator inhibitor-1 levels and polymorphisms
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Arch Pathol Lab Med 126:1401-4. 2002
    ..To review the published evidence of a relationship between levels of plasminogen activator inhibitor-1 (PAI-1) or the 4G/5G polymorphism of the PAI-1 gene and the occurrence of venous thromboembolic disease...
  2. doi request reprint Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
    ..001). Our findings reinforce the link between angiogenesis and TF expression in PCa. We suggest further exploration of TF-mediated pathways leading to increased tumor aggressiveness in PCa, and the possible use of anti-TF agents in PCa...
  3. pmc Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, The James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Transfusion 53:382-93. 2013
    ..We present here in vitro modeling data on the functional effects of exposure of PLTs to ABO antibodies...
  4. ncbi request reprint A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications
    Nicole M Kuderer
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Cancer 110:1149-61. 2007
    ....
  5. ncbi request reprint Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 110:2339-46. 2007
    ..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients...
  6. pmc The platelet as an immune cell-CD40 ligand and transfusion immunomodulation
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:251-60. 2009
    ..These effects come under the rubric of transfusion immunomodulation, which postulates that transfusion recipient biology, particularly immune function, is dramatically altered by transfusion of stored allogeneic blood...
  7. pmc Foxp3 regulates megakaryopoiesis and platelet function
    Jamie J Bernard
    Department of Environmental Medicine, University of Rochester, Rochester, NY 14642, USA
    Arterioscler Thromb Vasc Biol 29:1874-82. 2009
    ..Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets...
  8. pmc Prevention of venous thromboembolism in hospitalized patients with cancer
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4874-80. 2009
    ..In conclusion, most patients hospitalized with cancer are at high risk of venous thromboembolism, and thromboprophylaxis should be provided in the absence of active bleeding or a high bleeding risk...
  9. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
    ..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes...
  10. pmc Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 126:113-8. 2010
    ..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy...
  11. ncbi request reprint Ximelagatran: a new oral anticoagulant
    Charles W Francis
    Hematology Oncology Unit, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 610, Rochester, NY, USA
    Best Pract Res Clin Haematol 17:139-52. 2004
    ..Ximelagatran may be an alternative oral anticoagulant for patients currently taking vitamin K antagonists...
  12. ncbi request reprint Factor XIII polymorphisms and venous thromboembolism
    Charles W Francis
    Vascular Medicine Unit, University of Rochester School of Medicine and Dentistry, NY, USA
    Arch Pathol Lab Med 126:1391-3. 2002
    ..To review the relationship between factor XIII polymorphisms and venous thromboembolism...
  13. pmc Platelets and megakaryocytes contain functional nuclear factor-kappaB
    Sherry L Spinelli
    Department of Environmental Medicine, Box 850, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Arterioscler Thromb Vasc Biol 30:591-8. 2010
    ..We discovered that human megakaryocytes and platelets express the majority of NF-kappaB family members, including the regulatory inhibitor-kappaB (I-kappaB) and I-kappa kinase (IKK) molecules...
  14. doi request reprint Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study
    John Mongan
    University of Rochester Medical Center, Department of Medicine Hematology Oncology, Rochester, NY 14642, USA
    Thromb Res 129:760-4. 2012
    ..Thiazolidinediones (TZDs) are agonists of PPARγ and exert beneficial metabolic effects in patients with diabetes. They may also affect platelet function...
  15. pmc An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, USA
    Vox Sang 101:55-60. 2011
    ..Transfusion of ABO non-identical plasma, platelets and cryoprecipitate is routine practice even though adverse effects can occur...
  16. ncbi request reprint Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients
    Charles W Francis
    Department of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    N Engl J Med 356:1438-44. 2007
  17. ncbi request reprint American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...
  18. ncbi request reprint Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement
    Charles W Francis
    Department of Medicine, University of Rochester, Rochester, NY, USA
    N Engl J Med 349:1703-12. 2003
    ..The purpose of the present study was to determine whether a higher dose of ximelagatran is superior to warfarin...
  19. doi request reprint Prevention of VTE in patients having major orthopedic surgery
    Charles W Francis
    University of Rochester Medical Center, Rochester, NY 14642, USA
    J Thromb Thrombolysis 35:359-67. 2013
    ..Combination therapy consisting of an antithrombotic agent and mechanical device is probably more effective than either alone. The appropriate use of thromboprophylaxis after MOS results in reduced VTE with acceptable bleeding risks...
  20. ncbi request reprint Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Clin Cancer Res 13:2870-5. 2007
    ..We correlated TF expression with vascular endothelial growth factor (VEGF) expression, microvessel density, and venous thromboembolism in resected pancreatic cancer...
  21. ncbi request reprint Thromboembolism in hospitalized neutropenic cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 24:484-90. 2006
    ..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia...
  22. doi request reprint Vaginal bleeding in early pregnancy and circulating markers of thrombin generation
    David N Hackney
    Department of Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    J Matern Fetal Neonatal Med 25:1479-82. 2012
    ..To determine if subjects experiencing acute vaginal bleeding in early pregnancy have increased plasma markers of thrombin generation compared to nonbleeding controls...
  23. pmc Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles
    Denise M Ray
    University of Rochester Medical Center, Environmental Medicine, Rochester, New York 14642, USA
    Thromb Haemost 99:86-95. 2008
    ....
  24. ncbi request reprint Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis
    Ronald H Gottlieb
    Department of Radiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 648, Rochester, NY 14642, USA
    AJR Am J Roentgenol 180:241-5. 2003
    ..We compared patient outcomes using two protocols: one routinely and the other selectively evaluating the calves completely during sonographic assessment of the lower extremities in patients with suspected deep venous thrombosis...
  25. ncbi request reprint Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial
    Charles W Francis
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Ann Intern Med 137:648-55. 2002
    ..Ximelagatran, an oral direct thrombin inhibitor, has shown promising efficacy and tolerability in patients undergoing total hip or knee arthroplasty...
  26. ncbi request reprint Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty
    Clifford W Colwell
    Orthopaedic Surgery, Scripps Clinic, 11025 North Torrey Pines Road, Suite 140, La Jolla, CA 92037, USA
    J Bone Joint Surg Am 87:2169-77. 2005
    ....
  27. ncbi request reprint Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial
    Jean Noel Fiessinger
    Department of Vascular Medicine, Hopital Europeen Georges Pompidou, Paris, France
    JAMA 293:681-9. 2005
    ..Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism...
  28. ncbi request reprint Venous thromboembolism in patients with diffuse large B-cell lymphoma
    Rami S Komrokji
    Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
    Leuk Lymphoma 47:1029-33. 2006
    ..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis...
  29. ncbi request reprint Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
    Cancer 104:2822-9. 2005
    ..The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy...